Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Coronary diseaseDay 2

SOLACI-SOCIME 2022 | Treatment Consideration in Women: Results from the RECOVER III Study – By Dr. Alexandra Lansky

solaci
solaci
707
0

Disfrute esta conferencia magistral brindada por la Dra. Alexandra Lansky durante el Congreso SOLACI-SOCIME 2022 realizado en Expo Santa Fé, CDMX los días 4, 5 y 6 de agosto de 2022.

Tema: Treatment Consideration in Women: Results from the RECOVER III Study

Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

Previous article
The Best Moments of SOLACI-SOCIME 2022
Next article
SOLACI-SOCIME 2022 | The future of the innovation in cardiovascular interventions – Dr. Chaim Lotan
solaci
solaci

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

Dr. Omar Tupayachi - 0
The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

Dr. Omar Tupayachi - 0
In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

solaci - 0
This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

Dr. Andrés Rodríguez - 0
This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Chronic Ischemic cardiopathy

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

Dr. Andrés Rodríguez - 0
This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

Dr. Andrés Rodríguez - 0
The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

Dr. Omar Tupayachi - 0
The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...